Resverlogix initiated a research program dedicated to ApoA-I production and testing its therapeutic potential for disorders that affect cognitive function, such as Alzheimer's Disease.
Epidemiological and mechanistic evidence indicate a link between low ApoA-I/HDL and neurodegenerative diseases. Resverlogix says it has molecules that are potent and selective in raising plasma ApoA-I/HDL by increasing ApoA-I production, which may beneficially impact AD. The Alzheimer's program will be developed by RVX Therapeutics, a wholly owned subsidiary of Resverlogix, and does not signal a change in any other processes or programs currently underway at Resverlogix.
"There remains a great unmet need in this therapeutic area," stated Jan Johansson, senior vp of clinical affairs at Resverlogix. "The growing body of evidence illustrating the ApoA-I/HDL protective role in neurodegenerative diseases makes a compelling argument for our lead ApoA-I technology, NexVas PR."